Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Vascular targeting--a new approach to the therapy of solid tumors.

Burrows FJ, Thorpe PE.

Pharmacol Ther. 1994 Oct;64(1):155-74. Review.

PMID:
7846113
2.

Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach.

Yoshioka Y, Tsutsumi Y, Nakagawa S, Mayumi T.

Curr Vasc Pharmacol. 2004 Jul;2(3):259-70. Review.

PMID:
15320824
3.

Vascular endothelial growth factor as a marker of tumor endothelium.

Brekken RA, Huang X, King SW, Thorpe PE.

Cancer Res. 1998 May 1;58(9):1952-9.

4.

A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.

Burrows FJ, Watanabe Y, Thorpe PE.

Cancer Res. 1992 Nov 1;52(21):5954-62.

5.

Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Dvorak HF, Nagy JA, Dvorak AM.

Cancer Cells. 1991 Mar;3(3):77-85. Review.

PMID:
1711364
6.

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

Burrows FJ, Thorpe PE.

Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8996-9000.

7.

Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model.

Burrows FJ, Overholser JP, Thorpe PE.

Cell Biophys. 1994;24-25:15-25.

PMID:
7736519
8.

Vascular endothelial growth factor and vascular targeting of solid tumors.

Brekken RA, Thorpe PE.

Anticancer Res. 2001 Nov-Dec;21(6B):4221-9. Review.

PMID:
11908675
9.

Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats.

Ohizumi I, Tsunoda S, Taniguchi K, Saito H, Esaki K, Makimoto H, Wakai Y, Tsutsumi Y, Nakagawa S, Utoguchi N, Kaiho S, Ohsugi Y, Mayumi T.

Biochem Biophys Res Commun. 1997 Jul 18;236(2):493-6.

PMID:
9240467
10.

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.

Brekken RA, Thorpe PE.

J Control Release. 2001 Jul 6;74(1-3):173-81. Review.

PMID:
11489493
11.

[Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].

Chiron MF.

Bull Cancer. 1997 Dec;84(12):1135-40. Review. French.

12.

Immunoconjugates and immunotoxins for therapy of solid tumors.

Hellström I, Trail P, Siegall C, Firestone R, Hellström KE.

Cancer Chemother Pharmacol. 1996;38 Suppl:S35-6. Review. No abstract available.

PMID:
8765413
13.

Antibody-directed targeting of the vasculature of solid tumors.

Thorpe PE, Burrows FJ.

Breast Cancer Res Treat. 1995;36(2):237-51. Review.

PMID:
8534871
14.

VEGF as a mediator of tumor-associated immunodeficiency.

Ohm JE, Carbone DP.

Immunol Res. 2001;23(2-3):263-72. Review.

PMID:
11444391
15.
16.

Evolution of the therapeutic use of new monoclonal antibodies.

Colnaghi MI, Ménard S, Canevari S.

Curr Opin Oncol. 1993 Nov;5(6):1035-42. Review.

PMID:
8305536
17.

Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.

Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS.

Cancer Res. 1999 Jan 1;59(1):183-8.

18.
19.
20.

Targeting the vasculature of solid tumours.

Murray JC, Hewett PW, Martin SG.

QJM. 1996 Mar;89(3):165-7. No abstract available.

PMID:
8731559

Supplemental Content

Support Center